Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
GPC3 siRNA refers to small interfering RNA molecules designed to target and silence the expression of Glypican-3 (GPC3), a cell-surface heparan sulfate proteoglycan that is highly overexpressed in hepatocellular carcinoma (HCC) and other cancers. By binding to GPC3 mRNA, the siRNA triggers its degradation via the RNA-induced silencing complex (RISC), thereby inhibiting GPC3 protein translation. This knockdown suppresses tumor cell proliferation, induces apoptosis, and reverses epithelial-mesenchymal transition (EMT). GPC3 siRNA is widely utilized as a research tool in oncology studies and is being investigated in preclinical therapeutic formulations, often utilizing nanoparticle or liposomal delivery systems to target liver tumors.
- Other names
- Glypican-3 siRNAGlypican3 siRNAGlypican 3 siRNAGPC3 small interfering RNAGPC-3 small interfering RNAGPC 3 small interfering RNAsiGPC3siGPC-3siGPC 3siRNA-GPC3siRNA-GPC-3siRNA-GPC 3
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3 siRNA.